The next generation of metabolic research isn’t only investigating new hormone pathways. Researchers are also asking whether the same active compound could be developed in multiple formats — and potentially administered less frequently for long-term maintenance. VK2735 is one of the most interesting examples. Developed by Viking Therapeutics, VK2735 is an investigational dual receptor agonist...Read More

An increasingly important theme in metabolic research is the connection between whole-body metabolism and the liver. Pemvidutide is an investigational compound designed to explore that relationship. Previously known as ALT-801, pemvidutide is being developed by Altimmune as a dual receptor agonist targeting both GLP-1 and glucagon receptors. While that receptor combination isn’t unique, pemvidutide has...Read More

Metabolic research is increasingly connecting two areas that were once commonly discussed separately: metabolic health and liver health. Survodutide is one of the most advanced investigational compounds exploring that connection. Previously known as BI 456906, survodutide is a long-acting dual receptor agonist being investigated in Phase 3 clinical programmes for both obesity and metabolic dysfunction-associated...Read More

Most people following metabolic research are now familiar with GLP-1. But an emerging area of research asks what happens when GLP-1 receptor activity is combined with glucagon receptor activity in the same molecule. One of the most advanced examples is mazdutide. Previously known by the development code IBI362, mazdutide is a dual GLP-1 and glucagon...Read More

Much of today’s metabolic research conversation revolves around GLP-1 and related hormone pathways. But some of the most interesting research is happening somewhere completely different. One example is FGF21 — fibroblast growth factor 21. FGF21 is a naturally occurring signalling protein involved in the body’s response to metabolic and nutritional changes. Researchers are investigating engineered...Read More

As metabolic research expands, scientists are investigating an increasingly diverse range of biological pathways. One emerging compound attracting attention is petrelintide. Petrelintide is particularly interesting because its development isn’t based around adding another GLP-1 receptor agonist. Instead, researchers are investigating whether a long-acting amylin analogue can function as a distinct metabolic research approach. That makes...Read More

Metabolic research has produced an interesting scientific puzzle. Some investigational compounds are designed to activate the GIP receptor alongside GLP-1. Another emerging compound is investigating almost the opposite strategy. MariTide activates the GLP-1 receptor while blocking the GIP receptor. That apparent contradiction makes MariTide — formally known as maridebart cafraglutide — one of the more...Read More

As metabolic research expands beyond GLP-1, scientists aren’t only investigating combinations of more and more hormone pathways. Another approach is almost the opposite: becoming more selective. Eloralintide is an investigational compound from Eli Lilly that illustrates this strategy. Rather than combining GLP-1, GIP or glucagon activity, it is being studied as a selective amylin receptor...Read More

GLP-1 has transformed metabolic research, but the science is already moving into a much broader phase. Researchers are increasingly investigating multiple hormone pathways, new molecular designs, oral compounds and entirely different biological targets. The important development isn’t simply the arrival of another GLP-1-related molecule. It’s the diversification of the entire research field. Why Researchers Are...Read More

One of the most important developments in metabolic research isn’t another receptor target. It’s how these compounds are delivered. Many peptide-based medicines have traditionally required injection because peptides present a difficult pharmaceutical problem: the digestive system is specifically designed to break proteins and peptides down. Researchers are now trying to overcome that limitation. The result...Read More